含苯达莫司汀预处理方案在淋巴瘤自体移植中疗效及安全性分析  

Safety and efficacy of bendamustine in the conditioning regimen for autologous stem cell transplantation in patients with lymphoma

作　　者：刘昊东 刘丽萍[2] 孙振容 赖琴城 孙艳花[2] 王宝宏[2] 冉学红[2] LIU Haodong;LIU Liping;SUN Zhenrong;LAI Qincheng;SUN Yanhua;WANG Baohong;RAN Xuehong(Affiliated Hospital of Weifang Medical University,School of Clinical Medicine,Weifang Medical University,Weifang,261053,China;Department of Hematology,Weifang People’s Hospital)

机构地区：[1]潍坊医学院附属医院(临床医学院)潍坊医学院,山东潍坊261053 [2]潍坊市人民医院血液内科

出　　处：《临床血液学杂志》2022年第11期817-820,共4页Journal of Clinical Hematology

摘　　要：目的:探讨含苯达莫司汀的移植预处理方案[BeEAM(苯达莫司汀+依托泊苷+阿糖胞苷+马法兰)和BeEAC(苯达莫司汀+依托泊苷+阿糖胞苷+环磷酰胺)]在淋巴瘤自体造血干细胞移植(ASCT)中的疗效及安全性。方法:回顾性分析2020年10月—2022年5月在潍坊市人民医院血液科接受ASCT的13例非霍奇金淋巴瘤患者,分析造血重建时间,并评估疗效及不良反应。结果:ASCT前完全缓解10例,部分缓解3例。13例患者移植后均造血重建,中性粒细胞中位植活时间10(9~16)d,血小板中位植活时间14(9~22)d。移植后中位随访11(3~19)个月,患者移植后3个月完全缓解率为84.6%(11/13),主要的2级以上不良反应为发热性中性粒细胞减少、恶心、呕吐、腹泻、口腔黏膜炎,无移植相关死亡。结论:BeEAM和BeEAC预处理后ASCT均是治疗恶性淋巴瘤安全、有效的方法,其远期疗效尚待长期随访观察。Objective:To explore the safety and efficacy of bendamustine in the conditioning regimen for autologous hematopoietic stem cell transplantation(ASCT)in patients with lymphoma.Methods:From October 2020 to May 2022,13 patients with malignant lymphoma who underwent ASCT in our hospital were retrospectively analyzed.The time of hematopoietic reconstitution was analyzed,and the curative effect and adverse events were evaluated.Results:Ten patients achieved complete remission and 3 patients achieved partial remission hefore ASCT.All 13 patients achieved hematopoietic reconstitution after ASCT.The median engraftment time of neutrophils was 10(9-16)days,and the median engraftment time of platelets was 14(9-22)days.The median follow-up was 11(3-19)months after ASCT,and the complete remission rate was 84.6%(11/13)at 3 months after transplantation.The main adverse events above grade 2 were febrile neutropenia,nausea,vomiting,diarrhea,and oral mucositis.There were no transplant-related death.Conclusion:ASCT after BeEAM and BeEAC conditioning is a safe and effective method for the treatment of malignant lymphoma.The long-term efficacy of the conditioning regimen needs to be evaluated by long-term follow-up.

关 键 词：自体造血干细胞移植 淋巴瘤 苯达莫司汀 预处理方案 

分 类 号：R733.4[医药卫生—肿瘤]